We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 16 for:    lung cancer | Kitchener, Canada

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04335292
Recruitment Status : Recruiting
First Posted : April 6, 2020
Last Update Posted : June 23, 2022
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Mark Vincent, Lawson Health Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 1, 2024
Estimated Study Completion Date : June 1, 2024